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KAJIAN MENGENAI PERANAN KALSIUM FOSFAT PRODUK DALAM 
MENENTUKAN KEMATANGAN DAN PATENSI PEMBULUH DARAH FISTULA 
ABSTRAK 
Terdapat peningkatan pesakit penyakit buah pinggang peringkat akhir yang memerlukan 
rawatan hemodialisis di seluruh dunia. Akses vaskular untuk rawatan hemodialysis kekal 
sebagai komponen utama, tetapi malangnya, penyelenggaraan akses ini masih menjadi 
cabaran utama. Tempoh kematangan ‘arteriovenous fistula’ (AVF) adalah dipengaruhi oleh 
faktor-faktor pembolehubah seperti umur, kehadiran aterosklerosis, kalsifikasi vaskular 
kesan daripada produk kalsium fosfat dan kadar urea yang tinggi.  
 
 Kajian ini dihasilkan disebabkan kekurangan kajian mengenai kesan produk kalsium 
fosfat dan kesan deposit kalsium pada lapisan initima AVF (berdasarkan pemerhatian pada 
sampel tisu AVF) dalam menentukan kematangan dan patensi fistula. Kajian prospektif ini 
telah dijalankan di Pusat Sumber Penyakit Buah Pinggang Kronik, Hospital Universiti Sains 
Malaysia bermula Januari 2016 sehingga Mei 2016. Seramai seratus dua puluh satu pesakit 
yang layak terpilih dan terlibat menjalani pembedahan AVF dibawah seliaan Unit Sains 
Rekonstruktif. Pesakit hemodialysis yang berumur lapan belas tahun ke atas, belum pernah 
menjalani prosedur yang melibatkan salur darah utama (central vein) dan menjalani 
pembedahn AVF dimasukkan ke dalam kajian ini. Kriteria pengecualian adalah seperti 
penyakit vaskular periperal, stenosis salur darah vena utama, kecacatan pada bahagian tubuh 
untuk AVF dan penyakit vasculitis. 
 x 
 Di kalangan 121 pesakit yang dipilih, masing-masing mencapai tempoh kematangan 
normal dan lewat sebanyak 59 (48.8 %) dan 62 (51.2 %). Min umur untuk kematangan 
normal AVF adalah 55.7 tahun, manakala kematangan lewat AVF adalah 58.5 tahun. Produk 
kalsium fosfat tidak mempunyai kesan yang signifikan ke atas faktor kelewatan kematangan 
AVF (p value = 0.53); dengan didapati min (SD) produk kalsium fosfat adalah rendah dalam 
kumpulan AVF lewat matang iaitu 3.16 mmol/L (0.99) berbanding kumpulan normal 
kematangan AVF iaitu 3.35 mmol/L (1.28). Kesan deposit kalsium pada lapisan intima juga 
tidak menunjukkan keputusan yang signifikan pada faktor kematangan AVF (p value = 
0.30). Terdapat 13 (21.0%) sampel tisu AVF yang mempunyai deposit kalsium yang 
menunjukkan kelewatan kematangan AVF, manakala sebanyak 15 (25.0%) sampel tisu AVF 
yang menunjukkan kematangan normal. Hubungkait antara kalsium deposit dan lewat 
matang AVF  juga tidak menunjukkan keputusan yang signifikan, p value 0.59. 
 
 Kesimpulannya, produk kalsium fosfat tidak mempengaruhi kematangan AVF dan 
juga patensi AVF. Kesan kalsium deposit pada lapisan intima AVF juga tidak 
mempengaruhi tahap kematangan AVF. Namun, faktor konfounders dan faktor penghalang 
yang mempengaruhi kajian ini perlu diambil kira.     
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ABSTRACT 
There has been an increasing trend of end stage renal disease patients requiring 
haemodialysis treatment worldwide. Vascular access remains the key component of 
haemodialysis treatment, unfortunately, the maintenance of this access remains a 
challenging problem. The maturity of arteriovenous fistula is influenced by variable factors 
such as age, presence of atherosclerosis, vascular calcification as result from calcium 
phosphate product and uremia. 
This study had been done due to lack of study and evidence on effect of calcium 
phosphate product with correlation of calcium deposition in intima layer in determining 
AVF maturation and patency. This prospective study was performed in Chronic Kidney 
Disease (CKD) Resource Center, Hospital Universiti Sains Malaysia between Jan 2016 to 
May 2016. One hundred and twenty one patients were eligible for this study who underwent 
AVF creation under Reconstructive Science Unit HUSM. Patients above 18 years old with 
End Stage Renal Disease requiring regular hemodialysis were included in this study with no 
previous intervention of the central vein. Exclusion criteria included peripheral vascular 
disease, central venous stenosis, vascular access site deformity and vasculitic disease.  
 
 Among the selected 121 subjects, 59 (48.8%) and 62 (51.2%) achieved normal and 
delayed maturation respectively. The mean age for normal AVF maturation was 55.7 years, 
while delayed arteriovenous maturation was 58.5 years. Calcium phosphate product was not 
associated with delayed AVF maturation (p value 0.53); with lower mean (SD) calcium 
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phosphate product was observed in delayed mature AVF, 3.16 mmol/L (0.99) compare to 
normal mature AVF group, 3.35 mmol/L (1.28). There was no association between calcium 
deposition and delayed maturation of AVF (p value = 0.30). In delayed AVF group, there 
were 13 samples (21.0%) showed calcium deposition, whereas in normal maturation AVF 
group, there were 15 samples (25.0%) showed calcium deposition. Correlation between 
calcium depositions in intima layer with delayed maturation of AVF also showed no 
significant result with p value 0.59.   
   
 In conclusion, calcium phosphate product and calcium deposition based on tissue 
biopsy have no effect on AVF maturation and patency. However few considerations for 
confounding factors and limitation need to be taken.   
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CHAPTER 1: INTRODUCTION 
 
1.1 Research Background  
 
Statistic from National Kidney Foundation have shown that 10% of the population 
worldwide is affected by chronic kidney disease (CKD), and millions died each year because 
they do not have access to affordable treatment. According the 2010 Global Burden of 
Disease study, chronic kidney disease was ranked 27
th 
in the list of causes of total number of 
deaths worldwide in 1990, but rose to 18
th 
in 2010. This degree of movement up the list was 
second to that for HIV and AIDs. (National Kidney Foundation). 
 
Fresenius Medical Care in 2012 showed globally by end 2012, 3,010,000 patients are 
being treated for ESRD and, with a ~7% growth rate, this figure continues to increase 
significantly higher rate than the world population. The growth of ESRD patients is five 
times the world population growth (1.3%) and continues growing beyond all normal 
expectations, showing no signs of reaching a steady state within the next two decades 
(Moeller et al., 2002). Factors contributing to this growth include globally ageing, multi-
morbid population, higher life expectancy of treated ESRD patients and increasing access of 
a generally younger patient population to treatment. This disease present a significantly 
challenge to 21
st
 century global health policy. 
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       ( Fresenius Medical Care 2012) 
 
Figure 1: Development of global ESRD and dialysis prevalence value since 2000 ( patients 
per million population) 
 
 Renal replacement therapy (RRT) remains the most important tool for all patients 
with end stage renal disease (ESRD) to support their life expectancy. There are 
haemodialysis, peritoneal dialysis or renal transplantation. The replacement of renal function 
by hemodialysis (HD) demonstrated for the first time that at least the most vital functions of 
a complex organ could be replaced by a man-made device. The Founding Father of dialysis 
is the Scottish chemist Thomas Graham in 1861. The first recovery of a patient undergoing 
HD for acute renal failure (ARF) was reported by Kolff in 1945, paving the way for a 
rapidly worldwide expanding treatment of ARF with dialysis. The concept of applying HD 
to patients with end-stage chronic renal failure (ESRF), first pioneered by Alwall in Sweden 
as far back as 1948, became reality in 1960 when Scribner, Quinton et al. designed an 
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external arteriovenous by pass made of Teflon tubing which allowed a permanent access to 
the bloodstream without requirement of permanent anticoagulation. The Teflon AV shunt, 
later improved with the use of a silicone rubber material (Silastic) has been the cornerstone 
for implementing the long-term treatment of ESRF patients with maintenance HD. The next 
major breakthrough in this area consisted in the surgically created AV fistula performed in 
1966 by Cimino, Brescia et al. which considerably reduced the complications encountered 
with AV shunts. 
 
Dialysis continues to be the most frequent type of RRT because of the low rate of 
renal transplantation, strictly related to insufficient organ donation to meet demand. As a 
consequence, there is increasing demand of haemodialysis among ESRD patients and 
arteriovenous fistula (AVF) is widely regarded as the gold standard of vascular access. In 
1997 (updated in 2001), The National Kidney Foundation Dialysis Outcomes Quality 
Initiative (DOQI) proposed guidelines that AVF be constructed in at least 50% of permanent 
hemodialysis access procedures, to improve quality of life and outcome in patients with end-
stage renal disease. An additional DOQI goal was to achieve an AVF prevalence of 40% in 
all hemodialysis patients.  
 
 AVFs are regarded as the preferred vascular access in hemodialysis patients due to 
their primary patency and patient survival beneﬁts. The prevalence of fistulas among 
hemodialysis patients reflects both national, regional, and local practice differences as well 
as patient-specific demographic and clinical factors. Increasing fistula prevalence requires 
increasing fistula placement, improving maturation of new fistulas, and enhancing long-term 
patency of mature fistulas for dialysis. Fistulas have been identified as the best outcome and 
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can be placed with the least expense and complication rate when compared to a catheter or 
graft. Several recent initiatives have focused on vascular access and ways to improve 
outcomes. The National Foundation for Kidney Dialysis Outcomes Quality Initiative (K-
DQOL), End Stage Renal Disease Clinical Performance Measures (CPM) and Fistula First 
Initiative (FFI) have provided guidelines that mandate fistula access in patients on 
hemodialysis (Vasquez, 2009).  
 
Several factors contribute to the creation of fistula in a patient including timing of 
referral for dialysis and vascular access, type of fistula placed, patient demographics, 
preference of the nephrologist, surgeon, and dialysis nurses, and vascular anatomy of the 
patient (Allon and Robbin, 2002). Vascular access should be easy to use, reliable and have 
minimal risk to the individual receiving haemodialysis. The ideal vascular access should 
provide safe and effective therapy by enabling the removal and return of blood via an 
extracorporeal circuit. It also improved morbidity, mortality and cost-effectiveness.  
 
 Arteriovenous fistula (AVF) is associated with the lowest incidence of morbidity and 
mortality compare to other modality of vascular access for hemodialysis. For maturation of 
AVF to occur, the main principal is vessel remodeling. This means that AVF must be of 
adequate size to allow for successful repetitive cannulation and provide good blood flow to 
support the hemodialysis prescription. 
 
Based on United States Renal Data System (USRDS), AVF prevalence has risen to 
42% as of June 2006. The unanticipated consequence of aggressive AVF placement is the 
 5 
high proportion of AVFs failure to mature. Approximately 25-30 years ago, only 10% of 
new AVFs failed to mature, in subsequent years, it has increased to 20-50% (Allon and 
Robbin, 2002). Hence, there is a challenging issue need to maintain a good quality access as 
the fundamental of the treatment of haemodialysis treatment. 
 
 The non- matured AVF has emerged as the major obstacle to dialysis patients. 
Fistula failure is classified as primary failure and secondary failure. Primary failure is 
defined as the failure of the fistula prior to its first cannulation while secondary failure is 
defined as failure after a radiologic intervention such as angioplasty or stent or surgical 
revision (Hammes, 2011). It is well known from several studies that there is significant 
primary failure rate for all AV fistulas after its placement (Schild, 2004; Biuckians, 2008; 
December 2008). The common causes of fistula failure include inflow problems due to 
inadequate arterial supply, anastomotic stenosis that result from trauma during creation, or 
outflow problems of the venous segment. Outflow problems may occur because of 
underlying fibrosis of the vein (Hammes, 2011).  
 
 Numerous studies have been performed in the attempt to correlate the factors 
responsible for failure of AVF maturity. Various predicting factors have been studied in this 
matter and the understanding of the pathogenesis of AVF non maturation is imperative to 
achieve the KDOQI AVF goals. The importance of identifying potential patient factors 
predisposing to failure of AVF maturity may provide opportunities in improving dialysis 
vascular access outcomes. This will guide clinicians into deciding the optimal timing and 
patient selections prior vascular access creation. Hence will benefit patients and reduce 
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potential complications from the unfavorable surgical interventions.  
 
 Various clinical factors will be considered including patients’ demographic factors, 
comorbidities and biochemical factors related to the Delayed of AVF maturity. In view of 
disturbances in mineral and bone metabolism are common complications in CKD; these will 
be the alarming factors in influencing the arteriovenous fistula maturation together with the 
risk of vascular calcification and reduced arterial compliance (Moe and Chen, 2004).  
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1.2 Rationale Of The Study 
 
This study is designed to evaluate the role of calcium phosphate product in arteriovenous 
fistula maturation and patency in End Stage Renal Disease patient in Kelantan. There is high 
prevalence of delayed arteriovenous maturation and multiple postulated factors contributing 
to it including comorbidities, type of fistula and biochemical levels especially calcium 
phosphate product level. We hope this study will provide valuable information on calcium 
phosphate product level in influencing the arteriovenous fistula maturation while enabling us 
to further improve the outcome of the created AVF. 
 
 The study findings will help in identifying the acceptable calcium phosphate product 
in achieving an effective and good quality vascular access in ESRD patients. In long term, 
the cost effectiveness of AVF placement will be improved hence reducing the unwanted 
complications.  
 
 This study will also provide local data in Kelantan and develop new information 
about the microfactors (calcium phosphate product) that can potentially delay arteriovenous 
fistula maturation. It is hoped through the gained information will provide a useful guidance 
in patients selections for vascular access placement and subsequently preventing 
unnecessary AVF failure. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1  CKD MBD and vascular calcification 
 
As kidney function declines, there is progressive deterioration in mineral homeostasis with 
disruption of normal serum and  tissue concentrations of calcium, phosphorus and changes 
in circulating levels of hormones  including parathyroid hormone (PTH), 25-hydroxyvitamin 
D (25 (OH)D), 1,25-dihdroxyvitamin D (1.25(OH)2D) and other vitamin D metabolites, 
fibroblast growth factor-23 (FGF-23), and growth hormone. Later, kidney fails to respond 
adequately to PTH, downregulation of vitamin D receptor and resistance to the actions of 
PTH.  These minerals and endocrine functions are critically important in regulation of bone 
formation and recently there has been an increasing concern on extraskeletal calcification 
that may result from the therapies used to correct these abnormalities (KDIGO 2009). 
  
KDIGO 2009 has come out with new term CKD Mineral and Bone Disorder (CKD 
MBD) in order to describe the broader clinical syndrome encompassing mineral, bone and 
vascular abnormalities that developed as a complication of Chronic Kidney Disease. The 
definition of CKD-MBD is a systemic disorder of mineral and bone metabolism due to CKD 
by either one or combination of the following : 
a) abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism 
b) abnormalities in bone turnover, mineralization, volume, linear growth or strength 
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c)  vascular or other soft tissue calcification 
 
The mechanism of vascular calcification in CKD and ESRD remain an active area of 
research. Calcification is an important part of atherosclerosis process and generally develops 
within intimal layer of vessel wall (Lee T et al, 2013). In CKD population, coronary artery 
and generalized vascular calcification is exceedingly more prevalent and more severe 
compare with that normal population. Hence, cardiovascular event is the leading mortality in 
ESRD patients (Lee T et al, 2013). 
 
Longitudinal studies have shown that the progression of vascular calcification seems 
to be modifiable by the choice of phosphate binder. Few studies comparing treatment 
between calcium containing phosphate binders and non calcium phosphate binders showed 
inconsistency of results in terms of calcification progression. Some showed calcification 
progress with calcium containing phosphate binders, but treatment with non calcium based 
phosphate binders was associated with lack of calcification progression (Russo et al, Kidney 
Int 2007). Therefore, calcification of fistula also contributed partly by type of phosphate 
binder used.  
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2.2 Factors Affecting Arteriovenous Fistula Maturation 
 
The factors affecting maturity of AVF are postulated by multifactorial including (Lok et al, 
2006): 
a) sociodemographic factors; age and gender 
b) comorbidities such as diabetes mellitus, cardiovascular disease, hypertension, 
atherosclerotic disease and peripheral vascular disease  
c) adequacy of vessels and type of fistula  
d) biochemical; calcium phosphate product, hyperphosphatemia, uremia which result in 
vascular calcification 
 
Several studies have provided some insights into the problem of delayed AVF 
maturity, unfortunately there is still limited understanding behind the failed AVF. 
Thrombosis and/or delayed in maturity are reasons of primary AVF failure, however risk 
factors for primary failures are not limited to the site and vascular diameters (Rodriguez et 
al., 2000). A study conducted from 1997 to 1999 showed the primary failure rate between 
10-20% (Pavcnik et al., 2008). A recent meta-analysis has demonstrated 15.3% primary 
failure rate for native AVF (Irish et al., 2009).  
 
  Delayed maturation of fistulas will lead to prolonged dependence on dialysis 
catheters. This phenomenon is well known to be associated with the risk of infection, central 
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venous thrombosis or stenosis and social inconvenience to the patients. In this study, we are 
focusing on role of calcium phosphate product in maturation and patency of AVF. There are 
few studies on these factors, but each study has its own limitation, end points and clinical 
factors consideration. Identifying the role of calcium phosphate product risk factor in 
delaying maturation or fistula failure will help the clinicians in order to provide suitable 
treatment as primary and secondary prevention.   
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2.2.1 Calcium Phosphate Product On Vascular Calcification  
 
The presence of increased vascular calcification in patients with CKD has been known, 
however the extent to which vascular calcification impacts on cardiovascular disease and 
mortality has recently been appreciated. Studies have reported increased coronary artery 
calcification and the extent of vascular calcification in CKD compared with the general 
population. There is a relationship between increased vascular calcification and loss of bone 
mineral content, with recent experimental studies revealing the mechanisms link these two 
processes (Davies and Hruska, 2001; Moe, 2006).  
  
The mechanisms of vascular calcification in CKD and ESRD remain an active area 
of research. Vascular calcifications classically occur in two locations, the intima and the 
media. Intimal calcifications are part of the atherosclerosis process. They are limited to large 
and medium-sized conduit arteries. Although they are not specific to CKD, calcifications of 
coronary arteries are twofold to fivefold more frequent in CKD patients than in age-matched 
individuals with angiographically proven coronary artery disease (Reynolds et al., 2005). 
Medial calcifications occur in elastin fibers around vascular smooth muscle cell (VSMC) in 
the absence of atherosclerosis are seen primarily in CKD or diabetes. 
 
 Local and systemic calcium-regulatory proteins as well as inhibitory extracellular 
factors are also involved in the pathogenesis of vascular calcification. Vascular calcification 
is the end result from an imbalance between cellular mediators which promote and inhibit 
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mineralization. In addition to proper homeostasis of vascular mineralization, the current 
research to date has demonstrated that one major mechanism involved in regulation of 
vascular calcification is vascular smooth muscle cell (VSMC) damage (Shroff and 
Shanahan, 2007). Normally, VSMCs play an important role in inhibiting calcification, but in 
pathologic environments such as kidney disease their normal function is compromised and 
they develop osteogenic phenotypic changes that favor deposition of minerals that leads to 
calcification (Shroff and Shanahan, 2007). It is also hypothesized that when VSMCs become 
apoptotic, they release apoptotic bodies which accumulate calcium and initiate the 
calcification process (Proudfoot et al., 2000; Shroff and Shanahan, 2007; Shroff et al., 
2008). Furthermore, VSMCs have been reported to bud matrix vesicles from their plasma 
membranes. These small membrane bound particles form a microenvironment capable of 
concentrating calcium and phosphate and allowing for crystal nucleation (Proudfoot et al., 
2000; Reynolds et al., 2004; Shroff and Shanahan, 2007). 
 
In patients with chronic kidney failure, increased serum calcium phosphate product 
and hyperphosphatemia are important contributors to the higher incidence of arterial 
calcifications and cardiovascular events. Hyperphosphatemia, by accelerating the 
progression of secondary hyperparathyroidism, increases serum PTH and bone loss. High 
PTH itself induces increases in intracellular calcium and abnormal lipid metabolism that 
promote soft tissue calcifications. Phosphorus-induced and PTH induced bone loss elevates 
calcium phosphate product and, most likely, the expression of factors that mediate the strong 
association between bone loss and arterial calcification, such as bone-associated proteins.  
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Direct effects of phosphorus on vascular pathology include the regulation of vascular 
cell proliferation as well as the induction of the expression of the osteoblast-specific bone-
forming proteins, Cbfa-1 and osteocalcin. The control of serum phosphorus levels in patients 
with uremia may reduce vascular calcification not only by decreasing calcium-phosphate 
product but also by reducing serum PTH, thus ameliorating the active and yet incompletely 
understood processes common for vascular calcification and bone loss. In the last 10 years, 
several mechanisms have been proposed for phosphate regulation of vascular calcification, 
involving not only deposition of calcium and phosphate in the vasculature, but also direct 
activation of genes associated with osteoblastic functions in vascular smooth muscle cells 
(Jakoby IV and Semenkovich, 2000).  
 
 Recent studies have demonstrated phosphate regulation of vascular calcification 
and provided some insights into the mechanisms for phosphate induction of metastatic 
calcifications. In vivo studies by Kuro-o et al., in the KLOTHO-gene mutant mice with a 
phenotype that resembles human aging, demonstrated that, in the presence of normal serum 
creatinine, albumin, cholesterol, and triglyceride levels and with only a mild increase in 
serum calcium levels (from 9.5 to 10.6 mg/dl), a two-fold increase in serum phosphate levels 
resulted in increased calcium phosphate product as well as the development of vascular 
calcifications and osteoporosis that were unrelated to malnutrition, abnormal lipid 
metabolism, or chronic renal failure (Kurosu et al., 2005). Hyperphosphatemia was the main 
determinant of the increased calcium phosphate product. In the study by Jono et al., 2000 
which assessed the contribution of hyperphosphatemia per se on vascular calcification, the 
study demonstrate that, high phosphorus levels in the incubation media (2.0 mmol/L 
 15 
phosphate) enhanced calcification in human aortic smooth muscle cells. In conclusion, 
elevation of calcium phosphate product and high phosphate per se could induce vascular 
calcification.  
 
 The calcium crystal that accumulates in the vasculature and contributes to vascular 
calcification is calcium apatite, which is the mineral found in bone, and the discovery of 
bone-related factors in vessels when calcified adds stronger evidence to the intimate 
relationship between bone disorder and vascular calcification. With high bone turnover, 
associated with elevated parathyroid hormone (PTH) levels, the egress of phosphate from 
bone is increased and this condition is associated with increased vascular calcification. There 
are many studies have been reported a positive relationship between vascular calcification 
and serum calcium, phosphate and calcium phosphate product (Goodman WG, Goldin J, 
Kuizon BD et al, NEJM 2000, London GM, Guerin AP, Marchais SJ et al NDT 2003.). 
Vascular calcification induced by calcium and phosphate excess and uraemia, are the major 
risk factors and is independently associated with cardiovascular events and death. This is 
well demonstrated in the Figure 3 as follow. The optimal control of mineral metabolism, 
especially hyperphosphatemia with non-calcium based phosphate binders, has been shown to 
be effective to reduce vascular calcification, and attenuation of arterial stiffness (Toussaint 
and Kerr, 2007). 
 
 Vascular calcification, previously thought to be precipitation of excess minerals at 
sites of damage, is now recognised as an active process involving a complex interaction of 
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inducers and inhibitors with dysregulation of the normal equilibrium, as in CKD, resulting in 
the development of vascular calcification. The extent of vascular calcification and the degree 
of arterial stiffening, closely interrelated are independent predictors of cardiovascular 
mortality in both the general and CKD populations. There is emerging evidence that 
vascular calcification is an active cell-mediated process, exacerbated by both uraemia and 
abnormalities in mineral and bone metabolism and it has been well reported that increased 
serum levels of calcium, phosphate and PTH are associated with increased mortality as well 
as greater vascular calcification (Toussaint and Kerr, 2007).  
 
 The calcium–phosphorous product is considered a theoretical indicator of the risk 
of mineral crystallization in soft tissues. However, as deposition and dissolution of calcium 
salts is a dynamic process, there is no absolute level of calcium–phosphorous below which 
precipitation will not occur. KDIGO CKD MBD 2009, indicated a threshold product of   
4.18 mmol²/L² based on a comparison of patients with and without visceral calcifications, 
suggesting that this level represents the saturation product of the two ions.  
 
 Velentzas et al. mentioned that inflammation might trigger calcium deposition in 
the arteries. In this context it should also be considered that CRP, being a member of the 
pentraxin family, binds to damaged tissue in a calcium dependent manner and shows 
membrane association with multiple calcium ions. Moreover, CRP binds to enzymatically 
degraded LDL (E-LDL) particles in normal atherosclerotic lesions, inducing complement 
activation and promoting the development and progression of the atherosclerotic lesion. 
There is a general consensus about CRP being a marker of cardiovascular risk both in non-
 17 
uraemic  and uraemic subjects. It could also be a promoter of the progression of 
atherosclerotic lesions.  
 
 
                             
Figure 2: Impact of hyperphosphatemia on vascular calcification 
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Figure 3: Pathogenesis of vascular calcification 
Adapted from Kidney International; Official Journal of International Society of Nephrology, 
Dec 2008  
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2.2.2 Adequacy Of Vessels And Types Of Arteriovenous Fistula (AVF)  
 
 In order for AVF to mature, there must be sufficient delivery of intra-access blood flow and 
pressure, depending upon on adequate cardiac output / systemic blood pressure. A good 
quality feeding (arterial) vessel is mandatory, which will be able to transmit a high pressure 
to an accepting, unrestricted (i.e. no anastomotic stenosis), compliant and distensible outflow 
(venous) vessel (Lok et al., 2006). Adequacy of the fistula flow rate depends on the pressure 
gradient and the total resistance in the fistula circuit including the proximal artery, fistula 
anastomosis, and the downstream vein. Hence, both coronary artery disease and peripheral 
vascular disease were predictors of failure to mature, each indicating diseased inflow and 
outflow in reference to the anastomosis, respectively.  
 
 Haemodialysis patients have vascular properties that impair dilatation. Their arteries 
may develop increased intimal and medial thickening, medial calcification and increased 
stiffness with decreased flow-mediated dilatation. Artery is generally narrower than the vein 
hence, the artery is the chief source of vascular resistance in a new fistula. Thus, arterial 
dilatation plays an important role in fistula maturation. These observations have led to 
suggestions that vascular compliance should be assessed preoperatively. So far, there are 
many factors influencing the maturation of fistula and one of the commonest cause is arterial 
elasticity (Morad, 2012).  
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 Radiocephalic fistula (RCF) is the first recommended fistula; however it often fails 
to mature in the elderly patient with underlying vascular disease, particularly in diabetics 
(Miller,1999; Rodriquez, 2000). The second recommended fistula is the brachiocephalic 
fistula (BCF) due to high failure rate of RCF. The third recommended fistula is the 
brachiobasilic fistula (BBF), which usually involves a two steps surgical procedure and may 
be difficult to cannulate given the medial location of the basilic vein.  
 
AVF have a relatively high rate of primary failure, due to either normal thrombosis 
or failure of the draining vein to dilate adequately to mature. The rate of primary failure may 
be substantially higher in forearm, as compared to upper arm fistulas (brachiocephalic or 
brachiobasilic). Primary failure rate has been reported as 66% in forearm fistulas, as 
compared with 41% among upper arm fistulas (Allon et al., 2001). Similarly, Hakaim, 
Nalbandian and Scott observed a 70% non-maturation rate for forearm fistulas among 
diabetic dialysis patients, as compared with 22% for upper arm fistulas (Ethier et al., 2008). 
In the recent study done in Alor Setar, it concludes that established peripheral arterial 
disease, distally placed fistula, lower mean arterial pressure and absence of post operative 
immediate thrill were significantly associated with premature failure of autogenous AVF 
(Najmi et al., 2012). 
 
  Based on multiple previous studies, we can conclude that distally placed fistula has 
higher primary failure rate than proximal placed fistula. It is likely associated with the 
anatomically larger diameter and feasible vessels in the proximal of the upper arm.  
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2.3 Assessment Of Arteriovenous Fistula (AVF) Maturation  
 
Several changes are critical for successful maturation of a new AVF. There must be 
adequate dilatation of vessels to a calibre large enough to be cannulated repeatedly with two 
large bore dialysis needles. Furthermore, the blood flow rate in the draining vein must 
increase sufficiently to accommodate the dialysis blood flow required to deliver adequate 
dialysis. To avoid vein collapse and recirculation, the access blood flow should exceed the 
desired dialysis blood flow by at least 100 mL/min. The mean dialysis blood flow varies 
substantially among countries: about 400 mL/min in the United States, 300 mL/min in 
Europe, and 200 mL/min in Japan (abstract; Dykstra et al, J Am Soc Nephrol 11:182A, 
2000). These differences also mean that the definition of a mature fistula can vary among 
countries. Finally, the fistula must be superficial enough for the landmarks to be appreciated 
and permit safe cannulation without infiltration.  
 
 There is marked variation in the published literature regarding the definition of a 
successful fistula. The definitions have included presence of a thrill or bruit, ability to use 
the fistula for at least one dialysis session, or ability to use the fistula reproducibly for 
dialysis for at least one month with a dialysis blood flow > 350 mL/ min. 
 
 Fistula maturation is usually assessed subjectively by means of physical examination. 
A mature fistula will typically have an easily palpable superficial vein of adequate diameter 
that facilitates easy cannulation. It will have a uniform thrill to auscultation and palpation 
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that indicates adequate blood flow without stenosis. The accessible draining vein needs to be 
more than 10 cm long to allow for rotation of needle sites and adequate distance between the 
cannulating needles. If the draining vein is too tortuous or too deeply located in the 
subcutaneous tissues, it will be difficult to cannulate (Morad, 2012). 
 
 Timing of first cannulation of an arteriovenous fistula remains a controversial 
subject, but has been the subject of a few investigations reported in the literature recently. 
Data from DOPPS show that a functional fistula should have an outflow vein that can be 
successfully cannulated 1 month postoperatively.  
 
 According to National Kidney Foundation. Am J Kidney Dis. 2006;48(suppl 1):S1-
S322, the assessment for maturation of AVF by definition is by which a fistula becomes 
suitable for cannulation and the parameters included are volume flow, wall thickness, and 
vascular diameter. In general, a mature fistula should be a minimum of 6 mm in diameter 
with discernible margins when a tourniquet is in place, less than 6 mm deep from skin and 
have a blood flow greater than 600 ml/min. As per the K/DOQI guidelines, all AVFs should 
be routinely evaluated at 4 weeks. By 4 weeks, normal postoperative edema will have 
resolved and it is expected that the majority of fistulae with have reached maximum flow. 
For evaluation for nonmaturation, it will be taken as 6 weeks after surgical creation if it does 
not meet the above criteria (Group, 2009).  
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CHAPTER 3: OBJECTIVE OF STUDY 
 
3.1 General Objective  
To determine the effect of calcium phosphate product in maturation and patency of native 
arteriovenous fistula among End Stage Renal Disease patients in Kelantan 
 
3.2 Specific Objectives 
1. To determine the association of calcium phosphate product with maturation 
of arteriovenous fistula   
2. To determine the mean of calcium phosphate product in patency of 
arteriovenous fistula  
3. To evaluate the association of calcium with microcalcification present in 
arteriovenous intima layer 
4. To determine correlation between calcium deposition on biopsy with delayed 
maturation 
 
3.3 Research Questions 
1. Do calcium phosphate product delayed arteriovenous fistula maturation in ESRD patients 
in Kelantan? 
2. Do patency of arteriovenous fistula in ESRD patients in Kelantan depend on level of 
calcium phosphate product ? 
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3. Do level of calcium level correlate with product deposition in intimal layer of AVF that 
lead to vascular calcification? 
 
3.4 Research Hypothesis   
The mean measurement of calcium phosphate product is an indicator of vascular 
calcification, which delayed the maturation of arteriovenous fistula in chronic kidney disease 
patients. 
There was no research hypothesis needed for the first objectives since they are answerable 
by simple descriptive analysis. 
 
Null Hypothesis 
The calcium phosphate product is not significantly associated with delayed maturation and 
patency of arteriovenous fistula in ESRD patients. 
 
Alternative hypothesis 
The calcium phosphate product is significantly associated with delayed maturation and 
patency of arteriovenous fistula in CKD patients. 
 
 
 
 
 
